Christopher N Kaufmann1, Adam P Spira1, Colin A Depp1, Ramin Mojtabai1. 1. Dr. Kaufmann and Dr. Depp are with the Department of Psychiatry, University of California, San Diego, La Jolla, California. Dr. Spira and Dr. Mojtabai are with the Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
Abstract
OBJECTIVE: Clinical guidelines suggest that benzodiazepines (BZDs) and non-BZD hypnotics (NBHs) be used on a short-term basis. The authors examined trends in long-term BZD and NBH use from 1999 to 2014. METHODS: Data included 82,091 respondents in the 1999-2014 waves of the National Health and Nutrition Examination Survey (NHANES). NHANES recorded medications used in the past 30 days on the basis of prescription bottles, and participants reported use duration. BZD and NBH use were categorized as short, medium, and long term, and time trends in use were assessed. RESULTS: BZD and NBH use increased from 1999 to 2014, driven by increases in medium- and long-term use, even after adjustment for age and race-ethnicity. In most years, only a fifth of current BZD or NBH users reported short-term use. CONCLUSIONS: Long-term BZD and NBH use has grown independent of U.S. demographic shifts. Monitoring of use is needed to prevent adverse outcomes.
OBJECTIVE: Clinical guidelines suggest that benzodiazepines (BZDs) and non-BZD hypnotics (NBHs) be used on a short-term basis. The authors examined trends in long-term BZD and NBH use from 1999 to 2014. METHODS: Data included 82,091 respondents in the 1999-2014 waves of the National Health and Nutrition Examination Survey (NHANES). NHANES recorded medications used in the past 30 days on the basis of prescription bottles, and participants reported use duration. BZD and NBH use were categorized as short, medium, and long term, and time trends in use were assessed. RESULTS:BZD and NBH use increased from 1999 to 2014, driven by increases in medium- and long-term use, even after adjustment for age and race-ethnicity. In most years, only a fifth of current BZD or NBH users reported short-term use. CONCLUSIONS: Long-term BZD and NBH use has grown independent of U.S. demographic shifts. Monitoring of use is needed to prevent adverse outcomes.
Entities:
Keywords:
Antianxiety agents; Benzodiazepines; Public health; Sedative/hypnotic drugs; Sleep disorders
Authors: Christopher N Kaufmann; Adam P Spira; G Caleb Alexander; Lainie Rutkow; Ramin Mojtabai Journal: Pharmacoepidemiol Drug Saf Date: 2015-12-29 Impact factor: 2.890
Authors: Timothy J Wilt; Roderick MacDonald; Michelle Brasure; Carin M Olson; Maureen Carlyle; Erika Fuchs; Imran S Khawaja; Susan Diem; Erin Koffel; Jeannine Ouellette; Mary Butler; Robert L Kane Journal: Ann Intern Med Date: 2016-05-03 Impact factor: 25.391
Authors: Earl S Ford; Anne G Wheaton; Timothy J Cunningham; Wayne H Giles; Daniel P Chapman; Janet B Croft Journal: Sleep Date: 2014-08-01 Impact factor: 5.849
Authors: Matthew E Hirschtritt; Vanessa A Palzes; Andrea H Kline-Simon; Kurt Kroenke; Cynthia I Campbell; Stacy A Sterling Journal: Am J Manag Care Date: 2019-12-01 Impact factor: 2.229
Authors: Andrew S Tubbs; Fabian-Xosé Fernandez; Sadia B Ghani; Jordan F Karp; Salma I Patel; Sairam Parthasarathy; Michael A Grandner Journal: J Clin Sleep Med Date: 2021-05-01 Impact factor: 4.062
Authors: Christopher N Kaufmann; Alison A Moore; Mark W Bondi; James D Murphy; Atul Malhotra; Laura A Hart Journal: Curr Sleep Med Rep Date: 2020-01-28